Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03222128 · ClinicalTrials.gov registry record · NA
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate
A NA study of Symptomatic Severe Aortic Stenosis, sponsored by Edwards Lifesciences.
- Completed
- Registry status
- NA
- Development phase
- 1,074
- Enrollment target
- 20
- Study locations
NCT03222128: Completed NA study of Symptomatic Severe Aortic Stenosis, sponsored by Edwards Lifesciences.
NCT03222128 is a NA study of Symptomatic Severe Aortic Stenosis that has completed, run by Edwards Lifesciences. The registered enrollment target is 1,074 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03222128, a NA study of Symptomatic Severe Aortic Stenosis, has completed, sponsored by Edwards Lifesciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,074 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, and severe aortic stenosis, and those with intermediate risk.
Conditions Studied
Interventions
- DEVICE TAVR
Study Locations (20)
California
- Scripps Green Hospital - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- Mercy General Hospital - Sacramento
- Stanford University Medical Center - Stanford
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
- Northshore - Evanston
- Prairie Education and Research Cooperative - Springfield
Florida
- Morton Plant Hospital - Clearwater
- University of Florida - Gainesville
Indiana
- Indiana University Health-Methodist Hospital - Indianapolis
- St. Vincent Medical Group, Inc./St. Vincent Heart Center of Indiana, LLC - Indianapolis
Colorado
- University of Colorado Hospital - Denver
District of Columbia
- Washington Hospital Center - Washington D.C.
Georgia
- Emory University - Atlanta
Iowa
- The University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,074 participants |
| Start Date | 2014-02-17 |
| Est. Completion | 2024-10-09 |
| Phase | NA |
What the finished NCT03222128 record still lists
NCT03222128 is an interventional study that assigns participants to a tested intervention. Its 1,074 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Symptomatic Severe Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention - of which TAVR is the first listed.
NCT03222128 names 20 study sites across 12 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT03222128 about?
NCT03222128 is a clinical study titled "PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate". The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, and severe aortic stenosis, and those with intermediate risk.
What is the current status of trial NCT03222128?
This trial is currently completed. It is a NA study. The enrollment target is 1,074 participants. The study started on 2014-02-17. Estimated completion is 2024-10-09.
What conditions does trial NCT03222128 study?
This clinical trial studies the following conditions: Symptomatic Severe Aortic Stenosis.
What interventions are being tested in trial NCT03222128?
The interventions under investigation include: TAVR (DEVICE).
Who is sponsoring clinical trial NCT03222128?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03222128 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Symptomatic Severe Aortic Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03222128's enrollment target sits among peer trials
1,074 96th of 2000 higher than 1,905 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI